TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:TAK - US8740602052 - ADR
14.29 USD
-0.17 (-1.18%)
14.29 USD
0 (0%)
TAK gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. TAK has an excellent profitability rating, but there are concerns on its financial health. TAK has a decent growth rate and is not valued too expensively. Finally TAK also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
TAK had positive earnings in the past year.
TAK had a positive operating cash flow in the past year.
Each year in the past 5 years TAK has been profitable.
In the past 5 years TAK always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.23%, TAK is in the better half of the industry, outperforming 78.65% of the companies in the same industry.
TAK has a Return On Equity of 0.46%. This is amongst the best in the industry. TAK outperforms 80.21% of its industry peers.
With a decent Return On Invested Capital value of 1.87%, TAK is doing good in the industry, outperforming 78.65% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for TAK is significantly below the industry average of 12.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.23% | ||
| ROE | 0.46% | ||
| ROIC | 1.87% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
1.3 Margins
Looking at the Profit Margin, with a value of 0.75%, TAK is in the better half of the industry, outperforming 78.65% of the companies in the same industry.
TAK's Profit Margin has improved in the last couple of years.
TAK has a Operating Margin of 8.46%. This is in the better half of the industry: TAK outperforms 79.69% of its industry peers.
TAK's Operating Margin has improved in the last couple of years.
TAK's Gross Margin of 64.60% is fine compared to the rest of the industry. TAK outperforms 72.92% of its industry peers.
TAK's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.46% | ||
| PM (TTM) | 0.75% | ||
| GM | 64.6% |
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), TAK is creating some value.
TAK has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TAK has more shares outstanding
The debt/assets ratio for TAK has been reduced compared to a year ago.
2.2 Solvency
TAK has an Altman-Z score of 1.14. This is a bad value and indicates that TAK is not financially healthy and even has some risk of bankruptcy.
TAK has a Altman-Z score of 1.14. This is comparable to the rest of the industry: TAK outperforms 55.73% of its industry peers.
The Debt to FCF ratio of TAK is 5.04, which is a neutral value as it means it would take TAK, 5.04 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of TAK (5.04) is better than 82.29% of its industry peers.
A Debt/Equity ratio of 0.61 indicates that TAK is somewhat dependend on debt financing.
TAK's Debt to Equity ratio of 0.61 is on the low side compared to the rest of the industry. TAK is outperformed by 67.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 5.04 | ||
| Altman-Z | 1.14 |
ROIC/WACC1.17
WACC1.6%
2.3 Liquidity
A Current Ratio of 1.36 indicates that TAK should not have too much problems paying its short term obligations.
TAK has a Current ratio of 1.36. This is in the lower half of the industry: TAK underperforms 72.92% of its industry peers.
A Quick Ratio of 0.76 indicates that TAK may have some problems paying its short term obligations.
The Quick ratio of TAK (0.76) is worse than 85.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.76 |
3. Growth
3.1 Past
The earnings per share for TAK have decreased strongly by -88.38% in the last year.
The Earnings Per Share has been growing by 19.20% on average over the past years. This is quite good.
TAK shows a decrease in Revenue. In the last year, the revenue decreased by -2.84%.
TAK shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.84% yearly.
EPS 1Y (TTM)-88.38%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%-112.87%
Revenue 1Y (TTM)-2.84%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%-5.38%
3.2 Future
The Earnings Per Share is expected to grow by 51.50% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 0.19% on average over the next years.
EPS Next Y112.39%
EPS Next 2Y79.28%
EPS Next 3Y51.5%
EPS Next 5YN/A
Revenue Next Year-1.23%
Revenue Next 2Y-0.38%
Revenue Next 3Y0.19%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 204.14, the valuation of TAK can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of TAK indicates a somewhat cheap valuation: TAK is cheaper than 76.56% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of TAK to the average of the S&P500 Index (26.15), we can say TAK is valued expensively.
The Price/Forward Earnings ratio is 20.16, which indicates a rather expensive current valuation of TAK.
Based on the Price/Forward Earnings ratio, TAK is valued a bit cheaper than the industry average as 77.60% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of TAK to the average of the S&P500 Index (36.22), we can say TAK is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 204.14 | ||
| Fwd PE | 20.16 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, TAK is valued cheaply inside the industry as 88.54% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, TAK is valued cheaper than 92.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.58 | ||
| EV/EBITDA | 9.78 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates TAK does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of TAK may justify a higher PE ratio.
A more expensive valuation may be justified as TAK's earnings are expected to grow with 51.50% in the coming years.
PEG (NY)1.82
PEG (5Y)10.63
EPS Next 2Y79.28%
EPS Next 3Y51.5%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.46%, TAK is a good candidate for dividend investing.
TAK's Dividend Yield is rather good when compared to the industry average which is at 6.81. TAK pays more dividend than 96.35% of the companies in the same industry.
TAK's Dividend Yield is rather good when compared to the S&P500 average which is at 2.32.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.46% |
5.2 History
The dividend of TAK has a limited annual growth rate of 1.18%.
TAK has been paying a dividend for at least 10 years, so it has a reliable track record.
TAK has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.18%
Div Incr Years2
Div Non Decr Years3
5.3 Sustainability
TAK pays out 935.06% of its income as dividend. This is not a sustainable payout ratio.
The dividend of TAK is growing, but earnings are growing more, so the dividend growth is sustainable.
DP935.06%
EPS Next 2Y79.28%
EPS Next 3Y51.5%
14.29
-0.17 (-1.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners43.43%
Inst Owner Change8.68%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap45.14B
Revenue(TTM)4.42T
Net Income(TTM)33.08B
Analysts73.68
Price Target16.25 (13.72%)
Short Float %0.34%
Short Ratio3.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.46% |
Yearly Dividend0.62
Dividend Growth(5Y)1.18%
DP935.06%
Div Incr Years2
Div Non Decr Years3
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-41.49%
Min EPS beat(2)-121.92%
Max EPS beat(2)38.94%
EPS beat(4)1
Avg EPS beat(4)-35.42%
Min EPS beat(4)-121.92%
Max EPS beat(4)38.94%
EPS beat(8)4
Avg EPS beat(8)-31.47%
EPS beat(12)6
Avg EPS beat(12)-33.69%
EPS beat(16)7
Avg EPS beat(16)-40.61%
Revenue beat(2)0
Avg Revenue beat(2)-6.4%
Min Revenue beat(2)-6.76%
Max Revenue beat(2)-6.04%
Revenue beat(4)0
Avg Revenue beat(4)-3.84%
Min Revenue beat(4)-6.76%
Max Revenue beat(4)-0.48%
Revenue beat(8)4
Avg Revenue beat(8)3.03%
Revenue beat(12)7
Avg Revenue beat(12)3.44%
Revenue beat(16)11
Avg Revenue beat(16)3.69%
PT rev (1m)-7.92%
PT rev (3m)-6.18%
EPS NQ rev (1m)3.88%
EPS NQ rev (3m)11.23%
EPS NY rev (1m)-5.98%
EPS NY rev (3m)-4.73%
Revenue NQ rev (1m)-0.25%
Revenue NQ rev (3m)-0.02%
Revenue NY rev (1m)-0.13%
Revenue NY rev (3m)-0.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 204.14 | ||
| Fwd PE | 20.16 | ||
| P/S | 1.58 | ||
| P/FCF | 7.58 | ||
| P/OCF | 5.83 | ||
| P/B | 0.98 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.78 |
EPS(TTM)0.07
EY0.49%
EPS(NY)0.71
Fwd EY4.96%
FCF(TTM)1.89
FCFY13.2%
OCF(TTM)2.45
OCFY17.17%
SpS9.03
BVpS14.58
TBVpS-3.27
PEG (NY)1.82
PEG (5Y)10.63
Graham Number4.79
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.23% | ||
| ROE | 0.46% | ||
| ROCE | 3.03% | ||
| ROIC | 1.87% | ||
| ROICexc | 1.99% | ||
| ROICexgc | 8.07% | ||
| OM | 8.46% | ||
| PM (TTM) | 0.75% | ||
| GM | 64.6% | ||
| FCFM | 20.88% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
ROICexc(3y)2.76%
ROICexc(5y)2.73%
ROICexgc(3y)14.61%
ROICexgc(5y)14.15%
ROCE(3y)4.25%
ROCE(5y)4.14%
ROICexgc growth 3Y-6.2%
ROICexgc growth 5Y8.09%
ROICexc growth 3Y-3.88%
ROICexc growth 5Y10.72%
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
F-Score6
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 5.04 | ||
| Debt/EBITDA | 3.9 | ||
| Cap/Depr | 37.3% | ||
| Cap/Sales | 6.28% | ||
| Interest Coverage | 3.04 | ||
| Cash Conversion | 107.4% | ||
| Profit Quality | 2788.5% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.76 | ||
| Altman-Z | 1.14 |
F-Score6
WACC1.6%
ROIC/WACC1.17
Cap/Depr(3y)69.03%
Cap/Depr(5y)56.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)9.44%
Profit Quality(3y)309.71%
Profit Quality(5y)308.48%
High Growth Momentum
Growth
EPS 1Y (TTM)-88.38%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%-112.87%
EPS Next Y112.39%
EPS Next 2Y79.28%
EPS Next 3Y51.5%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.84%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%-5.38%
Revenue Next Year-1.23%
Revenue Next 2Y-0.38%
Revenue Next 3Y0.19%
Revenue Next 5YN/A
EBIT growth 1Y-31.07%
EBIT growth 3Y-0.52%
EBIT growth 5Y13.39%
EBIT Next Year445.18%
EBIT Next 3Y77.79%
EBIT Next 5YN/A
FCF growth 1Y613.62%
FCF growth 3Y-8.86%
FCF growth 5Y9.4%
OCF growth 1Y24.54%
OCF growth 3Y-2%
OCF growth 5Y9.54%
TAKEDA PHARMACEUTIC-SP ADR / TAK FAQ
What is the ChartMill fundamental rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
ChartMill assigns a fundamental rating of 5 / 10 to TAK.
What is the valuation status of TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
ChartMill assigns a valuation rating of 5 / 10 to TAKEDA PHARMACEUTIC-SP ADR (TAK). This can be considered as Fairly Valued.
What is the profitability of TAK stock?
TAKEDA PHARMACEUTIC-SP ADR (TAK) has a profitability rating of 7 / 10.
Can you provide the expected EPS growth for TAK stock?
The Earnings per Share (EPS) of TAKEDA PHARMACEUTIC-SP ADR (TAK) is expected to grow by 112.39% in the next year.
How sustainable is the dividend of TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
The dividend rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) is 7 / 10 and the dividend payout ratio is 935.06%.